Metaboliczne aspekty działania leków beta-adrenolitycznych – część I Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
kwi 13, 2010
Słowa kluczowe:
leki β-adrenolityczne, aktualna pozycja wśród leków kardiologicznych
##plugins.themes.bootstrap3.article.main##
Abstrakt
Leki β-adrenolityczne są niejednorodną grupą leków, o bardzo szerokich wskazaniach i licznych przeciwwskazaniach. Niemniej, bez tej grupy leków nie sposób wyobrazić sobie dzisiaj farmakoterapię chorób sercowo-naczyniowych. Poza klasycznymi wskazaniami, takimi jak: choroba niedokrwienna serca i zawał serca, nadciśnienie tętnicze, przewlekła niewydolność serca i zaburzenia rytmu, nowoczesne β-adrenolityki mają je rozszerzone o cukrzycę, zaburzenia lipidowe i niewydolność nerek. Autorzy artykułu podsumowują aktualną wiedzę o tej fascynującej grupie leków.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Światowiec, A., & Kuch , M. (2010). Metaboliczne aspekty działania leków beta-adrenolitycznych – część I . Medycyna Faktów , 3(1(6), 88-92. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2619
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Bristow M.R., Port J.D., Kelly R.A.: Treatment of heart failure: pharmacologic methods. W: Heart Disease: A Textbook of Cardiovascular Medicine, sixth edition Braunwald E., Zippes D.P., Libby P. (red.). W.B. Saunders Company, Philadelphia 2001: 562-599.
2. Frishman W.H.: Carvedilol. N. Engl. J. Med. 1998; 339: 1759-1765.
3. Dickstein K., Cohen-Solal A., Filippatos G. et al. Wytyczne 2008 Europejskiego Towarzystwa Kardiologicznego dotyczące rozpoznawania i leczenia ostrej oraz przewlekłej niewydolności serca. Kardiologia Polska 2008; 66 suplement IV, 389-454.
4. Hunt S.A., Abraham W.T., Chin M.H. et al.: American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physician and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: 154-235.
5. López-Sendón J., Swedberg K., McMurray J. et al.: Expert consensus document on beta-adrenergic receptor blockers. Eur. Heart J. 2004; 25: 1341-62.
6. Gheorghiade M., Goldstein S.: Beta-blockers in the post-myocardial infarction patients. Circulation 2002; 106: 394-398.
7. Gottlieb S.S., McCarter R.J., Vogel R.A. et al.: Effect of beta-blockade on mortality among high-risk and low risk patients after myocardial infarction. N. Engl. J. Med. 1998; 339; 489-497.
8. Norwegian Timolol Trial Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N. Engl. J. Med. 1981; 304: 801-807.
9. Hjalmarson A., Elmfeldt D., Herlitz J. et al.: Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981; 2: 823-827.
10. BHAT Research group: A randomized trial of propranolol in patients with acute myocardial infarction. Mortality results. JAMA 1982; 247: 1707-1714.
11. The Miami Research Group: Metoprolol in acute myocardial infarction – randomized placebo-controlled trial. Eur. Heart J. 1985; 6: 199-226.
12. ISIS-1 Collaborative Group: Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction. Lancet 1986; 2: 57-66.
13. Roberts R., Rogers W.J., Mueller H.S. et al.: Immediate versus differed beta blockade following thrombolytic therapy in patients with acute myocardial infraction. Results of the Thrombolysis in Myocardial Infarction (TIMI IIB). Circulation 1991; 83: 422-437.
14. Yusuf S., Lessen J., Pet J. et al.: Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated c ontrolled trials. J. Hypertens. 1993; 11(suppl. 4): S61-S73.
15. Freemantle N., Cleland J., Young P. et al.: Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 26: 1730-1737.
16. Beta-Blocker Pooling Project Research Group: Subgroup findings from randomised trials in post-myocardial infarction patients. Eur. Heart J. 1988; 9: 8-16.
17. Bertrand M.E., Simoons M.L., Fox K.A. et al.; Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology: Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2002; 23: 1809-1840.
18. Waagstein F.: Beta-blockers in congestive heart failure: the evolution of a new treatment concept-mechanism of action and clinical implications. J. Clin. Basic. Cardiol. 2002; 5: 215-223.
19. Rauls R.A., Tan Y., Knuepfer M.M.: Central beta-adrenoceptors mediate phasic and sustained components of hemodynamic responses to acute behavioral stress. Brain Res. 2005; 1048: 98-107.
20. Hedblad B., Wikstrand J., Janzon L. et al.: Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-1726.
21. Wiklund O., Hulthe J., Wikstrand J. et al.: Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33: 572-577.
22. Sipahi I., Tuzcu E.M., Wolski K.E. et al.: Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann. Intern. Med. 2007; 147: 10-18.
23. Heidland U.E., Strauer B.E.: Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-82.
2. Frishman W.H.: Carvedilol. N. Engl. J. Med. 1998; 339: 1759-1765.
3. Dickstein K., Cohen-Solal A., Filippatos G. et al. Wytyczne 2008 Europejskiego Towarzystwa Kardiologicznego dotyczące rozpoznawania i leczenia ostrej oraz przewlekłej niewydolności serca. Kardiologia Polska 2008; 66 suplement IV, 389-454.
4. Hunt S.A., Abraham W.T., Chin M.H. et al.: American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physician and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: 154-235.
5. López-Sendón J., Swedberg K., McMurray J. et al.: Expert consensus document on beta-adrenergic receptor blockers. Eur. Heart J. 2004; 25: 1341-62.
6. Gheorghiade M., Goldstein S.: Beta-blockers in the post-myocardial infarction patients. Circulation 2002; 106: 394-398.
7. Gottlieb S.S., McCarter R.J., Vogel R.A. et al.: Effect of beta-blockade on mortality among high-risk and low risk patients after myocardial infarction. N. Engl. J. Med. 1998; 339; 489-497.
8. Norwegian Timolol Trial Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N. Engl. J. Med. 1981; 304: 801-807.
9. Hjalmarson A., Elmfeldt D., Herlitz J. et al.: Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 1981; 2: 823-827.
10. BHAT Research group: A randomized trial of propranolol in patients with acute myocardial infarction. Mortality results. JAMA 1982; 247: 1707-1714.
11. The Miami Research Group: Metoprolol in acute myocardial infarction – randomized placebo-controlled trial. Eur. Heart J. 1985; 6: 199-226.
12. ISIS-1 Collaborative Group: Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction. Lancet 1986; 2: 57-66.
13. Roberts R., Rogers W.J., Mueller H.S. et al.: Immediate versus differed beta blockade following thrombolytic therapy in patients with acute myocardial infraction. Results of the Thrombolysis in Myocardial Infarction (TIMI IIB). Circulation 1991; 83: 422-437.
14. Yusuf S., Lessen J., Pet J. et al.: Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated c ontrolled trials. J. Hypertens. 1993; 11(suppl. 4): S61-S73.
15. Freemantle N., Cleland J., Young P. et al.: Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 26: 1730-1737.
16. Beta-Blocker Pooling Project Research Group: Subgroup findings from randomised trials in post-myocardial infarction patients. Eur. Heart J. 1988; 9: 8-16.
17. Bertrand M.E., Simoons M.L., Fox K.A. et al.; Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology: Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2002; 23: 1809-1840.
18. Waagstein F.: Beta-blockers in congestive heart failure: the evolution of a new treatment concept-mechanism of action and clinical implications. J. Clin. Basic. Cardiol. 2002; 5: 215-223.
19. Rauls R.A., Tan Y., Knuepfer M.M.: Central beta-adrenoceptors mediate phasic and sustained components of hemodynamic responses to acute behavioral stress. Brain Res. 2005; 1048: 98-107.
20. Hedblad B., Wikstrand J., Janzon L. et al.: Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-1726.
21. Wiklund O., Hulthe J., Wikstrand J. et al.: Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33: 572-577.
22. Sipahi I., Tuzcu E.M., Wolski K.E. et al.: Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann. Intern. Med. 2007; 147: 10-18.
23. Heidland U.E., Strauer B.E.: Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-82.